載入中
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
前收盤價
US$2.25
+US$0.43 · +23.63%
盤中時間採用ET。市場資料可能有所延遲。
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
日內區間
目前US$2.25
52週區間
目前US$2.25
盤中時間採用ET。市場資料可能有所延遲。
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
日內區間
目前US$2.25
52週區間
目前US$2.25
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 646.5萬 USD | 635.3萬 USD | 570.5萬 USD | — | 284.2萬 USD |
| 毛利 | −646.5萬 USD | −635.3萬 USD | −570.5萬 USD | — | −284.2萬 USD |
| 研究與開發 | 4111萬 USD | 5047.7萬 USD | 4725.1萬 USD | 3767.2萬 USD | 2651萬 USD |
| 銷售、一般及管理費用 | 2572.7萬 USD | 3099.9萬 USD | 2890.1萬 USD | 2594.6萬 USD | 2114.6萬 USD |
| 營業費用 | 6037.2萬 USD | 7512.3萬 USD | 7044.7萬 USD | 6361.8萬 USD | 4765.6萬 USD |
| 利息收入 | 786.8萬 USD | 1078萬 USD | 1255萬 USD | 581.6萬 USD | 32.9萬 USD |
| 折舊和攤銷 | 646.5萬 USD | 635.3萬 USD | 570.5萬 USD | 341.6萬 USD | 284.2萬 USD |
| 營業利益 | −6683.7萬 USD | −8147.6萬 USD | −7615.2萬 USD | −6361.8萬 USD | −5049.8萬 USD |
| 淨利 | −5900.1萬 USD | −7078萬 USD | −6367.5萬 USD | −5792.4萬 USD | −5031.5萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$3.50
上漲空間 55.56%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM248.19萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI187.73萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF52.83萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC34.2萬0.03%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 ETFVTWO27.91萬0.00%180億 USD0.06%US$112.66+0.50%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM17萬0.14%1.17億 USD0.73%US$15.9402+0.25%
iShares Russell 2000 Growth ETFIWO12.16萬0.00%139.17億 USD0.24%US$356.78+0.94%
Global X - Russell 2000 ETFRSSL5.39萬—14.19億 USD0.08%US$109.09+0.21%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Russell 2000 ETFVTWOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Russell 2000 Growth ETFIWOGlobal X - Russell 2000 ETFRSSLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
